切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2013, Vol. 07 ›› Issue (02) : 102 -106. doi: 10.3877/cma. j. issn.1674-0807.2013.02.006

论著

精神安慰加中草药治疗对乳痛症伴抑郁、焦虑情绪患者的作用
刘鹏熙1,(), 李薇晗1   
  1. 1.510120 广州,广东省中医院乳腺科
  • 收稿日期:2012-06-27 出版日期:2013-04-01
  • 通信作者: 刘鹏熙

Therapeutic effects of reassurance combined with Chinese herbal drugs on mastodynia patients with depression and anxiety

Peng-xi LIU1,(), Wei-han LI1   

  1. 1.Department of Breast Diseases, Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou 510120, China
  • Received:2012-06-27 Published:2013-04-01
  • Corresponding author: Peng-xi LIU
引用本文:

刘鹏熙, 李薇晗. 精神安慰加中草药治疗对乳痛症伴抑郁、焦虑情绪患者的作用[J/OL]. 中华乳腺病杂志(电子版), 2013, 07(02): 102-106.

Peng-xi LIU, Wei-han LI. Therapeutic effects of reassurance combined with Chinese herbal drugs on mastodynia patients with depression and anxiety[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2013, 07(02): 102-106.

目的

观察安慰疗法加中草药对乳痛症伴抑郁、焦虑情绪患者的临床疗效。

方法

选取本院2011 年3 月至11 月就诊的视觉模拟评分(VAS)≥6,抑郁自评量表评分(SDS)≥50,或/和焦虑自评量表评分(SAS)≥53 的乳痛症患者随机分为中草药组(n=32)和精神安慰加中草药联合治疗组(n=30),并用VAS 及Cardiff 乳房疼痛量表分别在治疗前、治疗后1 个月及2 个月评估疗效。 计量资料用t检验,组间比较用重复测量的方差分析,计数资料用卡方检验。

结果

中草药组治疗前VAS 为6.12±0.49, 治疗后2 个月为5.19±1.00, 差异有统计学意义(t=4.676,P=0.000);联合治疗组治疗前VAS 为6.27±0.69,治疗后2 个月为5.07±1.01,差异有统计学意义(t=5.835,P=0.000);但组间比较差异无统计学意义(P=0.585)。 在Cardiff 评分方面,中草药组治疗前为7.64±2.9,治疗后2 个月为5.55±2.32,差异有统计学意义(t=4.924,P=0.000);联合治疗组治疗前为7.05±2.4,治疗后2 个月为4.02±1.39,差异有统计学意义(t=8.096,P=0.000);组间比较差异有统计学意义(F=6.922, P=0.011)。

结论

对于伴有焦虑、抑郁情绪的乳痛症患者,中草药治疗有一定效果,在此基础上加上精神安慰可以进一步改善疗效。

Objective

To investigate the therapeutic effects of reassurance combined with Chinese herbal drugs on mastodynia patients with depression and anxiety.

Methods

The mastodynia patients admitted in our hospital from March to November 2011, with visual analogue scale(VAS)≥6, self-rating depressive scale (SDS)≥50 and self-rating anxiety scale (SAS)≥53, were enrolled in the study. They were randomized to receive either Chinese herbal therapy (CH group, n=32) or reassurance coupled with CH (RCH group, n=30) for two months. The intensity of mastodynia was assessed before treatment, after treatment 1 month and 2 months using visual analogue scale (VAS) and the Cardiff breast pain chart. Measurement data was analyzed using t-test, group comparison using repeated measurement ANOVA analysis, and count data using the chisquare test.

Results

VAS in CH group was 6.12±0.49 before treatment, 5.19±1.00 at 2 months after treatment and the difference was statistically significant(t=4.676,P=0.000). VAS in RCH group was 6.27±0.69 before treatment,5.07±1.01 at 2 months after treatment and the difference was statistically significant(F=6.922, P=0.011). Group comparison on VAS showed no statistical difference (P=0.585). Cardiff score in CH group was 7.64±2.9 before treatment, 5.55±2.32 at 2 months after treatment and the difference was statistically significant (t=4.924,P=0.000). Cardiff score in RCH group was 7.05±2.4 before treatment,4.02±1.39 at 2 months after treatment and the difference was statistically significant (t=8.096,P=0.000).Group comparison on Cardiff score showed statistical difference(F=6.922, P=0.011).

Conclusion

For the mastodynia patients with anxiety and depression, Chinese herbal therapy is effective, if combined with rassurance, the clinical outcome is more satisfactory.

表1 两组患者一般资料比较
图1 Cardiff 乳房疼痛量表 将乳房疼痛分为轻度、中度和重度三个等级,请用Ο 表示轻度,Δ 表示中等,θ 表示重度,无不适则不填,请用[]表示月经日期
图2 两组治疗前后VAS 评分
表2 治疗前后两组VAS
图3 两组治疗前后Cardiff 评分
表3 Cardiff 乳房疼痛指数
[1]
Srivastava A, Mansel RE, Arvind N, et al. Evidence-based management of mastalgia: a meta-analysis of randomised trials[J]. Breast,2007,16(5):503-512.
[2]
Olawaiye A, Withiam-Leitch M, Danakas G, et al. Mastalgia:a review of management [J]. J Reprod Med, 2005, 50(12):933-939.
[3]
Oksa S, Luukkaala T, Maenpaa JU. Toremifene use does not alter serum inhibin A and B levels during mid-luteal phase in women with premenstrual mastalgia [J]. Gynecol Endocrinol,2010,26(2):114-147.
[4]
Johnson KM,Bradley KA,Bush K,et al. Frequency of mastalgia among women veterans. Association with psychiatric conditions and unexplained pain syndromes [J]. J Gen Intern Med,2006,21 Suppl 3:S70-S75.
[5]
Pruthi S, Wahner-Roedler DL, Torkelson CJ, et al. Vitamin E and evening primrose oil for management of cyclical mastalgia:a randomized pilot study[J]. Altern Med Rev,2010,15(1):59-67.
[6]
Chung MS, Kim GH. Effects of Elsholtzia splendens and Cirsium japonicum on premenstrual syndrome[J]. Nutr Res Pract,2010,4(4):290-294.
[7]
Mansel RE, Goyal A, Preece P, et al. European randomized,multicenter study of goserelin (Zoladex) in the management of mastalgia [J]. Am J Obstet Gynecol,2004,191(6):1942-1949.
[8]
Parsay S, Olfati F, Nahidi S. Therapeutic effects of vitamin E on cyclic mastalgia[J]. Breast J,2009,15(5):510-514.
[9]
Joshi JV, Pandey SN, Galvankar P, et al. Prevalence of premenstrual symptoms:preliminary analysis and brief review of management strategies [J]. J Midlife Health,2010,1(1):30-34.
[10]
蒋蓓琦,张一楚. 乳痛症的诊断和处理[J]. 中国实用外科杂志,2000,20(5):307-309.
[11]
郭真,卢崇亮.乳腺增生症及其内分泌治疗[J]. 现代中西医结合杂志,2009,18(5):579-581.
[12]
卓睿,柴妤. 中药治疗乳腺增生多指标临床研究[J]. 辽宁中医药大学学报,2007,9(6):137-139.
[13]
王俊勤. 柴胡疏肝散加减治疗乳腺增生症[J]. 医学论坛杂志,2006,27(21):110.
[14]
王秀春. 柴胡疏肝散加减治疗乳腺增生病66 例[J]. 医学论坛杂志,2003,24(11):19-21.
[15]
Rosolowich V, Saettler E, Szuck B, et al. Mastalgia[J]. J Obstet Gynaecol Can,2006,28(1):49-71.
[16]
Ramirez AJ, Jarrett SR, Hamed H, et al. Psychosocial adjustment of women with mastalgia [J]. Breast,1995,4(1):48-51.
[17]
Barros AC, Mottola J, Ruiz CA, et al. Reassurance in the treatment of mastalgia[J]. Breast J,1999,5(3):162-165.
[1] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[10] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[11] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要